IBDEI0DP ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6592,2)
 ;;=^336732
 ;;^UTILITY(U,$J,358.3,6593,0)
 ;;=249.60^^55^568^47
 ;;^UTILITY(U,$J,358.3,6593,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6593,1,4,0)
 ;;=4^249.60
 ;;^UTILITY(U,$J,358.3,6593,1,5,0)
 ;;=5^Secondary DM w/ Neuro Complications
 ;;^UTILITY(U,$J,358.3,6593,2)
 ;;=^336734
 ;;^UTILITY(U,$J,358.3,6594,0)
 ;;=257.2^^55^568^31
 ;;^UTILITY(U,$J,358.3,6594,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6594,1,4,0)
 ;;=4^257.2
 ;;^UTILITY(U,$J,358.3,6594,1,5,0)
 ;;=5^Hypogonadism
 ;;^UTILITY(U,$J,358.3,6594,2)
 ;;=^88213
 ;;^UTILITY(U,$J,358.3,6595,0)
 ;;=255.42^^55^568^38
 ;;^UTILITY(U,$J,358.3,6595,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6595,1,4,0)
 ;;=4^255.42
 ;;^UTILITY(U,$J,358.3,6595,1,5,0)
 ;;=5^Mineralcorticoid Deficient
 ;;^UTILITY(U,$J,358.3,6595,2)
 ;;=^335241
 ;;^UTILITY(U,$J,358.3,6596,0)
 ;;=259.50^^55^568^2
 ;;^UTILITY(U,$J,358.3,6596,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6596,1,4,0)
 ;;=4^259.50
 ;;^UTILITY(U,$J,358.3,6596,1,5,0)
 ;;=5^Androgen Insensitivity,Unspec
 ;;^UTILITY(U,$J,358.3,6596,2)
 ;;=^336738
 ;;^UTILITY(U,$J,358.3,6597,0)
 ;;=275.5^^55^568^18
 ;;^UTILITY(U,$J,358.3,6597,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6597,1,4,0)
 ;;=4^275.5
 ;;^UTILITY(U,$J,358.3,6597,1,5,0)
 ;;=5^Hungry Bone Syndrome
 ;;^UTILITY(U,$J,358.3,6597,2)
 ;;=^336538
 ;;^UTILITY(U,$J,358.3,6598,0)
 ;;=793.2^^55^569^3
 ;;^UTILITY(U,$J,358.3,6598,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6598,1,4,0)
 ;;=4^793.2
 ;;^UTILITY(U,$J,358.3,6598,1,5,0)
 ;;=5^Abnormal Chest x-ray, other
 ;;^UTILITY(U,$J,358.3,6598,2)
 ;;=^273419
 ;;^UTILITY(U,$J,358.3,6599,0)
 ;;=277.6^^55^569^5
 ;;^UTILITY(U,$J,358.3,6599,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6599,1,4,0)
 ;;=4^277.6
 ;;^UTILITY(U,$J,358.3,6599,1,5,0)
 ;;=5^Alpha-1 antitrypsin deficiency
 ;;^UTILITY(U,$J,358.3,6599,2)
 ;;=^87463
 ;;^UTILITY(U,$J,358.3,6600,0)
 ;;=493.92^^55^569^6
 ;;^UTILITY(U,$J,358.3,6600,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6600,1,4,0)
 ;;=4^493.92
 ;;^UTILITY(U,$J,358.3,6600,1,5,0)
 ;;=5^Asthma, Acute Exacerbation
 ;;^UTILITY(U,$J,358.3,6600,2)
 ;;=^322001
 ;;^UTILITY(U,$J,358.3,6601,0)
 ;;=493.20^^55^569^11
 ;;^UTILITY(U,$J,358.3,6601,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6601,1,4,0)
 ;;=4^493.20
 ;;^UTILITY(U,$J,358.3,6601,1,5,0)
 ;;=5^COPD with Asthma
 ;;^UTILITY(U,$J,358.3,6601,2)
 ;;=COPD with Asthma^269964
 ;;^UTILITY(U,$J,358.3,6602,0)
 ;;=493.91^^55^569^7
 ;;^UTILITY(U,$J,358.3,6602,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6602,1,4,0)
 ;;=4^493.91
 ;;^UTILITY(U,$J,358.3,6602,1,5,0)
 ;;=5^Asthma, with Status Asthmat
 ;;^UTILITY(U,$J,358.3,6602,2)
 ;;=^269967
 ;;^UTILITY(U,$J,358.3,6603,0)
 ;;=491.21^^55^569^10
 ;;^UTILITY(U,$J,358.3,6603,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6603,1,4,0)
 ;;=4^491.21
 ;;^UTILITY(U,$J,358.3,6603,1,5,0)
 ;;=5^COPD Exacerbation
 ;;^UTILITY(U,$J,358.3,6603,2)
 ;;=COPD Exacerbation^269954
 ;;^UTILITY(U,$J,358.3,6604,0)
 ;;=494.0^^55^569^9
 ;;^UTILITY(U,$J,358.3,6604,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6604,1,4,0)
 ;;=4^494.0
 ;;^UTILITY(U,$J,358.3,6604,1,5,0)
 ;;=5^Bronchiectasis, chronic
 ;;^UTILITY(U,$J,358.3,6604,2)
 ;;=^321990
 ;;^UTILITY(U,$J,358.3,6605,0)
 ;;=494.1^^55^569^8
 ;;^UTILITY(U,$J,358.3,6605,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6605,1,4,0)
 ;;=4^494.1
 ;;^UTILITY(U,$J,358.3,6605,1,5,0)
 ;;=5^Bronchiectasis with exacerb
 ;;^UTILITY(U,$J,358.3,6605,2)
 ;;=^321991
 ;;^UTILITY(U,$J,358.3,6606,0)
 ;;=496.^^55^569^12
 ;;^UTILITY(U,$J,358.3,6606,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6606,1,4,0)
 ;;=4^496.
